OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in
point-of-care diagnostic tests and specimen collection devices,
today announced its financial results for the three and six months
ended June 30, 2019.
“Second quarter revenues were not what we had targeted due to a
three-day delayed shipment of HIV Self-Tests and ongoing softness
in the consumer genomics markets. However, our earnings were strong
and we continue to expect to deliver on and exceed our original
profit targets for the year notwithstanding market headwinds,” said
Stephen S. Tang, Ph.D., OraSure President and CEO. “We are
encouraged by the continued, annual double-digit growth in our
Microbiome line of business, as well as growth in the Disease Risk
Management sector of Consumer Genomics. On the Infectious Disease
side, we continue to expect annual double-digit growth in global
HIV testing revenues, driven by expanding international usage of
our HIV Self-Test product."
Financial and Business Highlights
- Net revenues for the second quarter of 2019 were $38.8 million,
an 11% decrease from the second quarter of 2018. Net product
revenues were $37.3 million, representing a 4% decrease from the
second quarter of 2018.
- Net revenues for the six months ended June 30, 2019 were $68.9
million, a 19% decrease from the comparable period of 2018. Net
product revenues were $65.6 million, representing a 15% decrease
from the first half of 2018.
- Molecular collection systems revenues including royalty income
and other revenues were $18.5 million during the second quarter of
2019, a decline of 4% from the second quarter of 2018. Molecular
collection systems revenues including royalty income and other
revenues were $30.3 million during the first half of 2019, a
decline of 23% from the same period in the prior year.
- Molecular collection systems product and service revenues were
$17.3 million and $27.9 million during the second quarter and first
half of 2019, respectively, which represents a 1% increase from the
second quarter of 2018 and a 22% decrease from the first six months
of 2018.
- Domestic and international sales of the Company’s OraQuick® HIV
products of $9.9 million in the second quarter of 2019 decreased
21% compared to the second quarter of 2018. Domestic and
international sales of the Company’s OraQuick® HIV products for the
six months ended June 30, 2019 of $18.2 million decreased 22%
compared to the comparable period of the prior year.
- Domestic sales of the Company’s OraQuick® HCV product of $2.1
million increased 22% over the second quarter of 2018. OraQuick®
HCV domestic sales for the six months ended June 30, 2019 were $3.9
million, a 17% increase from the comparable period of 2018.
- International sales of the Company’s OraQuick® HCV product of
$1.0 million decreased 33% for the second quarter of 2019 compared
to the second quarter of 2018. OraQuick® HCV international sales
for the six months ended June 30, 2019 were $2.4 million, a 14%
increase from the comparable period of 2018.
- Net income for the second quarter of 2019 was $4.4 million, or
$0.07 per share on a fully-diluted basis, which compares to net
income of $4.1 million, or $0.07 per share on a fully-diluted
basis, for the second quarter of 2018. Net income for the six
months ended June 30, 2019 was $1.1 million, or $0.02 per share on
a fully-diluted basis, which compares to net income of $2.0
million, or $0.03 per share on a fully-diluted basis, for the
comparable period of 2018. Net income for the current three and six
month periods included acquisition-related charges of $249,000 and
$1.5 million, respectively, representing the change in fair value
of contingent consideration associated with two recent
acquisitions. The current six month period also included $597,000
of transaction costs. These acquisition-related charges were
negligible for the current quarter on a per share basis and
approximated $0.03 per share for the first six months of 2019. Net
income for the second quarter and first six months of 2018 included
$2.2 million and $8.6 million, respectively, of transition costs
associated with executive management changes which occurred in
2018. These transition costs approximated $0.04 and $0.14 per
share, respectively, for the second quarter and first six months of
2018, and primarily consisted of non-cash stock compensation
charges.
- Cash and investments totaled $186.6 million at June 30,
2019.
Financial Results
Net product revenues for the second quarter of 2019 decreased 4%
from the comparable period of 2018, primarily as a result of lower
sales of the Company’s OraQuick® HIV and genomics products and
lower international sales of the Company’s OraQuick® HCV test,
partially offset by higher sales of the Company’s microbiome,
cryosurgical, and domestic HCV products.
Net product revenues for the first six months of 2019 decreased
15% from the comparable period of 2018, primarily as a result of
lower sales of the Company’s genomics and OraQuick® HIV products,
partially offset by increases in microbiome, cryosurgical systems,
and OraQuick® HCV sales.
International sales of the OraQuick® HIV Self-Test for the three
months ended June 30, 2019 and 2018 included $1.1 million and $1.7
million, respectively, of support payments under the Company’s
charitable support agreement with the Bill & Melinda Gates
Foundation (“Gates Foundation”). International sales of the
OraQuick® HIV Self-Test for the six months ended June 30, 2019 and
2018 included $1.8 million and $2.7 million, respectively, of
support payments.
Royalty income from a litigation settlement associated with a
molecular collection device was $1.1 million and $2.1 million for
the second quarters of 2019 and 2018, respectively, and $2.2
million and $3.7 million for the first six months of 2019 and 2018,
respectively. Other revenues, excluding royalty income, were
$445,000 and $2.7 million for the second quarters of 2019 and 2018,
respectively, and $1.1 million and $4.8 million for the first six
months of 2019 and 2018, respectively. Other revenues in both
periods decreased due to lower funding received from the U.S.
Biomedical Advanced Research Development Authority (BARDA) and
lower cost reimbursement from the Gates Foundation.
Gross profit percentage was 64% and 63% for the three and six
months ended June 30, 2019. Gross profit percentage for the three
and six months ended June 30, 2018 was 59% in both periods. Gross
profit percentage in both periods of 2019 benefited from improved
product mix associated with higher sales of higher gross profit
products and lower royalty expense, partially offset by lower other
revenues, and the lower margins generated by the Company’s newly
acquired subsidiaries, Novosanis and CoreBiome.
For the three months ended June 30, 2019, operating expenses
were $19.7 million, a decrease of $604,000 from the $20.3 million
reported for the three months ended June 30, 2018. The decrease was
due in part to the absence of $2.2 million of transition costs
associated with executive management changes that occurred in the
second quarter of 2018, partially offset by a non-cash charge of
$249,000 in the current quarter for the change in fair value of
contingent consideration associated with the recent acquisition of
CoreBiome and Novosanis, as well as by the incremental operating
expenses of CoreBiome and Novosanis. For the six months ended June
30, 2019, operating expenses were $41.6 million, a decrease of $3.7
million from the $45.3 million reported for the six months ended
June 30, 2018. This decrease was due in part to the absence of $8.6
million of transition costs associated with executive management
changes that occurred in the first half of 2018, partially offset
by a non-cash charge of $1.5 million in the first half of 2019 for
the change in fair value of contingent consideration associated
with the recent acquisition of CoreBiome and Novosanis as well as
by the incremental operating expenses of CoreBiome and Novosanis.
During the first six months of 2019, the Company also incurred
$597,000 of transaction costs associated with the recent
acquisitions. There were no similar acquisition costs in either
period of 2018.
The Company reported operating income of $5.3 million and $1.5
million in the second quarter and first six months of 2019,
respectively, compared to operating income of $5.6 million and $5.1
million in the second quarter and first six months of 2018,
respectively.
During the second quarter of 2019, the Company recorded income
tax expense of $1.4 million compared to $2.2 million recorded in
the second quarter of 2018. During the six months ended June 30,
2019, the Company recorded income tax expense of $1.4 million
compared to $4.2 million in the six months ended June 30, 2018. The
decrease in income tax expense in both periods reflects the lower
pre-tax income generated by the Company’s Canadian subsidiary, DNA
Genotek, and includes an income tax benefit generated by
Novosanis.
The Company’s cash and investment balance totaled $186.6 million
at June 30, 2019, compared to $201.3 million at December 31, 2018.
For the six months ended June 30 2019, the Company generated $4.7
million in cash from operations.
Third Quarter and Updated Full-Year 2019
Guidance
The Company expects third quarter 2019 net revenues to range
from $39.0 million to $40.5 million and is projecting net income of
approximately $0.04 per share to $0.05 per share. For full-year
2019, the Company is expecting net revenues to range from $165.0
million to $170.0 million and is projecting net income of $0.24 to
$0.26 per share. These projections do not account for the impact of
changes in the fair value of acquisition-related contingent
consideration or any potential transaction costs related to future
business development activity since those items cannot be fully
determined at this time. The downward revision to full-year revenue
expectations from $170.0 to $175.0 million for 2019 reflects
continued softness in the consumer genomics market and lower
royalties associated with that market. Nonetheless, the Company
continues to expect that genomics revenues excluding the single
largest customer, microbiome revenues, and global HIV testing
revenues will all grow by double digits in 2019 compared to
2018.
|
Financial
Data |
Condensed Consolidated Financial Data |
|
|
Three Months Ended |
|
Six Months Ended |
|
|
June 30, |
|
June 30, |
|
|
2019 |
|
2018 |
|
2019 |
|
2018 |
Results of Operations |
|
|
|
|
|
|
|
|
|
|
|
|
Net revenues |
|
$ |
38,826 |
|
$ |
43,625 |
|
$ |
68,948 |
|
$ |
85,612 |
Cost of products sold |
|
|
13,808 |
|
|
17,730 |
|
|
25,850 |
|
|
35,250 |
Gross profit |
|
|
25,018 |
|
|
25,895 |
|
|
43,098 |
|
|
50,362 |
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
4,535 |
|
|
4,261 |
|
|
8,906 |
|
|
8,336 |
Sales and marketing |
|
|
7,687 |
|
|
7,429 |
|
|
14,982 |
|
|
14,928 |
General and administrative |
|
|
7,262 |
|
|
8,647 |
|
|
16,192 |
|
|
22,038 |
Change in fair value of acquisition-related contingent
consideration |
|
|
249 |
|
|
— |
|
|
1,544 |
|
|
— |
Total operating expenses |
|
|
19,733 |
|
|
20,337 |
|
|
41,624 |
|
|
45,302 |
Operating income |
|
|
5,285 |
|
|
5,558 |
|
|
1,474 |
|
|
5,060 |
Other income |
|
|
524 |
|
|
736 |
|
|
1,048 |
|
|
1,148 |
Income before income
taxes |
|
|
5,809 |
|
|
6,294 |
|
|
2,522 |
|
|
6,208 |
Income tax expense |
|
|
1,411 |
|
|
2,173 |
|
|
1,382 |
|
|
4,206 |
Net income |
|
$ |
4,398 |
|
$ |
4,121 |
|
$ |
1,140 |
|
$ |
2,002 |
Earnings per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
0.07 |
|
$ |
0.07 |
|
$ |
0.02 |
|
$ |
0.03 |
Diluted |
|
$ |
0.07 |
|
$ |
0.07 |
|
$ |
0.02 |
|
$ |
0.03 |
Weighted average shares: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
61,709 |
|
|
61,100 |
|
|
61,621 |
|
|
60,983 |
Diluted |
|
|
62,128 |
|
|
62,244 |
|
|
62,191 |
|
|
62,379 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, |
|
|
|
Dollars |
|
|
|
|
Percentage of Total Net Revenues |
|
|
|
2019 |
|
2018 |
|
%Change |
|
|
2019 |
|
|
2018 |
|
Market |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Infectious disease testing |
|
$ |
13,348 |
|
$ |
15,919 |
|
(16 |
)% |
|
34 |
% |
|
36 |
% |
Risk assessment testing |
|
|
3,097 |
|
|
3,315 |
|
(7 |
) |
|
8 |
|
|
8 |
|
Cryosurgical systems |
|
|
3,518 |
|
|
2,392 |
|
47 |
|
|
9 |
|
|
6 |
|
Molecular collection systems |
|
|
17,304 |
|
|
17,192 |
|
1 |
|
|
45 |
|
|
39 |
|
Net product and service revenues |
|
|
37,267 |
|
|
38,818 |
|
(4 |
) |
|
96 |
|
|
89 |
|
Royalty income |
|
|
1,114 |
|
|
2,092 |
|
(47 |
) |
|
3 |
|
|
5 |
|
Other |
|
|
445 |
|
|
2,715 |
|
(84 |
) |
|
1 |
|
|
6 |
|
Net revenues |
|
$ |
38,826 |
|
$ |
43,625 |
|
(11 |
)% |
|
100 |
% |
|
100 |
% |
|
|
Six Months Ended
June 30, |
|
|
|
Dollars |
|
|
|
|
Percentage of Total Net Revenues |
|
|
|
2019 |
|
2018 |
|
%Change |
|
|
2019 |
|
|
2018 |
|
Market |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Infectious disease testing |
|
$ |
25,686 |
|
$ |
30,090 |
|
(15 |
)% |
|
37 |
% |
|
35 |
% |
Risk assessment testing |
|
|
5,934 |
|
|
6,316 |
|
(6 |
) |
|
9 |
|
|
7 |
|
Cryosurgical systems |
|
|
6,093 |
|
|
5,177 |
|
18 |
|
|
9 |
|
|
6 |
|
Molecular collection systems |
|
|
27,886 |
|
|
35,553 |
|
(22 |
) |
|
40 |
|
|
42 |
|
Net product revenues |
|
|
65,599 |
|
|
77,136 |
|
(15 |
) |
|
95 |
|
|
90 |
|
Royalty income |
|
|
2,198 |
|
|
3,694 |
|
(40 |
) |
|
3 |
|
|
4 |
|
Other |
|
|
1,151 |
|
|
4,782 |
|
(76 |
) |
|
2 |
|
|
6 |
|
Net revenues |
|
$ |
68,948 |
|
$ |
85,612 |
|
(19 |
)% |
|
100 |
% |
|
100 |
% |
|
|
Three Months Ended |
|
|
Six Months Ended |
|
|
|
June 30, |
|
|
June 30, |
|
|
|
2019 |
|
2018 |
|
%Change |
|
|
2019 |
|
|
2018 |
|
|
%Change |
|
OraQuick®
Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Domestic HIV |
|
$ |
4,460 |
|
$ |
5,189 |
|
(14 |
)% |
|
$ |
8,765 |
|
|
$ |
10,234 |
|
|
(14 |
)% |
International HIV |
|
|
5,422 |
|
|
7,397 |
|
(27 |
) |
|
|
9,423 |
|
|
|
13,067 |
|
|
(28 |
) |
Net HIV revenues |
|
|
9,882 |
|
|
12,586 |
|
(21 |
) |
|
|
18,188 |
|
|
|
23,301 |
|
|
(22 |
) |
Domestic HCV |
|
|
2,102 |
|
|
1,730 |
|
22 |
|
|
|
3,930 |
|
|
|
3,358 |
|
|
17 |
|
International HCV |
|
|
983 |
|
|
1,473 |
|
(33 |
) |
|
|
2,440 |
|
|
|
2,138 |
|
|
14 |
|
Net HCV revenues |
|
|
3,085 |
|
|
3,203 |
|
(4 |
) |
|
|
6,370 |
|
|
|
5,496 |
|
|
16 |
|
Net product revenues |
|
$ |
12,967 |
|
$ |
15,789 |
|
(18 |
)% |
|
$ |
24,558 |
|
|
$ |
28,797 |
|
|
(15 |
)% |
|
|
Three Months Ended |
|
|
Six Months Ended |
|
|
|
June 30, |
|
|
June 30, |
|
|
|
2019 |
|
2018 |
|
%Change |
|
|
2019 |
|
|
2018 |
|
|
%Change |
|
Molecular Collection Systems Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Genomics |
|
$ |
14,221 |
|
$ |
15,368 |
|
(7 |
)% |
|
$ |
22,269 |
|
|
$ |
32,456 |
|
|
(31 |
)% |
Microbiome |
|
|
2,975 |
|
|
1,824 |
|
63 |
|
|
|
5,300 |
|
|
|
3,097 |
|
|
71 |
|
Other |
|
|
108 |
|
|
— |
|
100 |
|
|
|
317 |
|
|
|
— |
|
|
100 |
|
Net product and service revenues |
|
|
17,304 |
|
$ |
17,192 |
|
1 |
|
|
|
27,886 |
|
|
$ |
35,553 |
|
|
(22 |
) |
Royalty income |
|
|
1,114 |
|
|
2,092 |
|
(47 |
) |
|
|
2,198 |
|
|
|
3,694 |
|
|
(40 |
) |
Other |
|
|
36 |
|
|
— |
|
100 |
|
|
|
259 |
|
|
|
— |
|
|
100 |
|
Total Molecular Collection Systems Revenues |
|
$ |
18,454 |
|
$ |
19,284 |
|
(4 |
)% |
|
$ |
30,343 |
|
|
$ |
39,247 |
|
|
(23 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Condensed
Consolidated Balance Sheets (Unaudited) |
|
|
|
June 30,
2019 |
|
December 31,
2018 |
Assets |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
72,567 |
|
$ |
88,438 |
Short-term investments |
|
|
74,446 |
|
|
68,134 |
Accounts receivable, net |
|
|
29,390 |
|
|
34,842 |
Inventories |
|
|
25,670 |
|
|
22,888 |
Other current assets |
|
|
7,185 |
|
|
5,010 |
Property, plant and equipment,
net |
|
|
27,793 |
|
|
24,299 |
Right of use assets, net |
|
|
5,147 |
|
|
— |
Intangible assets, net |
|
|
12,472 |
|
|
5,137 |
Goodwill |
|
|
29,280 |
|
|
18,521 |
Long-term investments |
|
|
39,555 |
|
|
44,752 |
Other non-current assets |
|
|
3,960 |
|
|
3,550 |
Total assets |
|
$ |
327,465 |
|
$ |
315,571 |
|
|
|
|
|
|
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
Accounts payable |
|
$ |
10,956 |
|
$ |
10,598 |
Deferred revenue |
|
|
3,914 |
|
|
3,521 |
Contingent consideration
obligation |
|
|
5,249 |
|
|
— |
Other current liabilities |
|
|
9,832 |
|
|
13,861 |
Long-term lease
liabilities |
|
|
4,196 |
|
|
— |
Long-term contingent
consideration obligation |
|
|
649 |
|
|
— |
Other non-current
liabilities |
|
|
4,448 |
|
|
4,213 |
Stockholders’ equity |
|
|
288,221 |
|
|
283,378 |
Total liabilities and stockholders’ equity |
|
$ |
327,465 |
|
$ |
315,571 |
|
|
Six Months Ended |
|
|
June 30, |
Additional Financial
Data (Unaudited) |
|
2019 |
|
2018 |
Capital expenditures |
|
$ |
5,513 |
|
$ |
4,484 |
Depreciation and
amortization |
|
$ |
3,610 |
|
$ |
3,746 |
Stock-based compensation |
|
$ |
1,848 |
|
$ |
11,262 |
Cash provided by operating
activities |
|
$ |
4,661 |
|
$ |
13,928 |
|
|
|
|
|
|
|
Conference Call
The Company will host a conference call and audio webcast for
analysts and investors to discuss the Company’s 2019 second quarter
results, certain business developments and updated financial
guidance, beginning today at 5:00 p.m. Eastern Time (2:00 p.m.
Pacific Time). On the call will be Dr. Stephen S. Tang, President
and Chief Executive Officer, and Roberto Cuca, Chief Financial
Officer. The call will include prepared remarks by management and a
question and answer session.
In order to listen to the conference call, please dial
844-831-3030 (Domestic) or 315-625-6887 (International) and
reference Conference ID #9973117 or go to OraSure Technologies’ web
site, www.orasure.com, and click on the Investor Relations
page. Please click on the webcast link and follow the prompts for
registration and access 10 minutes prior to the call. A replay of
the call will be archived on OraSure Technologies’ web site shortly
after the call has ended and will be available for seven days. A
replay of the call can also be accessed until midnight, August 13,
2019, by dialing 855-859-2056 (Domestic) or 404-537-3406
(International) and entering the Conference ID #9973117.
About OraSure Technologies
OraSure Technologies is empowering the global community to
improve health and wellness by providing access to accurate
essential information. OraSure is a leader in the development,
manufacture and distribution of point-of-care diagnostic tests,
molecular collection devices and other technologies designed to
detect or diagnose critical medical conditions. Its
first-to-market, innovative products include rapid tests for the
detection of antibodies to HIV and Hepatitis C (HCV) on the
OraQuick® platform, sample self-collection and stabilization
products for molecular applications, and oral fluid laboratory
tests for detecting various drugs of abuse. Together with its
wholly-owned subsidiaries (DNA Genotek, CoreBiome and Novosanis),
OraSure provides its customers with value-added, end-to-end
solutions that encompass tools, diagnostics and services. OraSure’s
portfolio of products is sold globally to various clinical
laboratories, hospitals, clinics, community-based organizations and
other public health organizations, research institutions,
distributors, government agencies, physicians’ offices, commercial
and industrial entities and consumers.
For more information on OraSure Technologies, please visit
www.orasure.com.
Important Information
This press release contains certain forward-looking statements,
including with respect to expected revenues and earnings/loss per
share. Forward-looking statements are not guarantees of future
performance or results. Known and unknown factors that could cause
actual performance or results to be materially different from those
expressed or implied in these statements include, but are not
limited to: ability to successfully manage and integrate
acquisitions of other companies in a manner that complements or
leverages our existing business, or otherwise expands or enhances
our portfolio of products and our end-to-end service offerings, and
the diversion of management’s attention from our ongoing business
and regular business responsibilities to effect such integration;
the expected economic benefits of acquisitions (and increased
returns for our stockholders), including that the anticipated
synergies, revenue enhancement strategies and other benefits from
the acquisitions may not be fully realized or may take longer to
realize than expected and our actual integration costs may exceed
our estimates; ability to market and sell products, whether through
our internal, direct sales force or third parties; impact of
significant customer concentration in the genomics business;
failure of distributors or other customers to meet purchase
forecasts, historic purchase levels or minimum purchase
requirements for our products; ability to manufacture products in
accordance with applicable specifications, performance standards
and quality requirements; ability to obtain, and timing and cost of
obtaining, necessary regulatory approvals for new products or new
indications or applications for existing products; ability to
comply with applicable regulatory requirements; ability to
effectively resolve warning letters, audit observations and other
findings or comments from the U.S. Food and Drug Administration
(“FDA”) or other regulators; changes in relationships, including
disputes or disagreements, with strategic partners or other parties
and reliance on strategic partners for the performance of critical
activities under collaborative arrangements; ability to meet
increased demand for the Company’s products; impact of replacing
distributors; inventory levels at distributors and other customers;
ability of the Company to achieve its financial and strategic
objectives and continue to increase its revenues, including the
ability to expand international sales; ability to identify,
complete, integrate and realize the full benefits of future
acquisitions; impact of competitors, competing products and
technology changes; reduction or deferral of public funding
available to customers; competition from new or better technology
or lower cost products; ability to develop, commercialize and
market new products; market acceptance of oral fluid or urine
testing, collection or other products; market acceptance and uptake
of microbiome informatics, microbial genetics technology and
related analytics services; changes in market acceptance of
products based on product performance or other factors, including
changes in testing guidelines, algorithms or other recommendations
by the Centers for Disease Control and Prevention (“CDC”) or other
agencies; ability to fund research and development and other
products and operations; ability to obtain and maintain new or
existing product distribution channels; reliance on sole supply
sources for critical products and components; availability of
related products produced by third parties or products required for
use of our products; impact of increased reliance on U.S.
government contracts; impact of negative economic conditions;
ability to maintain sustained profitability; ability to utilize net
operating loss carry forwards or other deferred tax assets;
volatility of the Company’s stock price; uncertainty relating to
patent protection and potential patent infringement claims;
uncertainty and costs of litigation relating to patents and other
intellectual property; availability of licenses to patents or other
technology; ability to enter into international manufacturing
agreements; obstacles to international marketing and manufacturing
of products; ability to sell products internationally, including
the impact of changes in international funding sources and testing
algorithms; adverse movements in foreign currency exchange rates;
loss or impairment of sources of capital; ability to attract and
retain qualified personnel; exposure to product liability and other
types of litigation; changes in international, federal or state
laws and regulations; customer consolidations and inventory
practices; equipment failures and ability to obtain needed raw
materials and components; the impact of terrorist attacks and civil
unrest; and general political, business and economic conditions.
These and other factors that could affect our results are discussed
more fully in our Securities and Exchange Commission (“SEC”)
filings, including our registration statements, Annual Report on
Form 10-K for the year ended December 31, 2018, Quarterly Reports
on Form 10-Q, and other filings with the SEC. Although
forward-looking statements help to provide information about future
prospects, readers should keep in mind that forward-looking
statements may not be reliable. The forward-looking statements are
made as of the date of this press release and OraSure Technologies
undertakes no duty to update these statements.
Company Contact: |
|
|
|
Roberto Cuca |
|
Jeanne
Mell |
Chief Financial Officer |
|
VP Corporate Communications |
610-882-1820 |
|
484-353-1575 |
Investorinfo@orasure.com |
|
media@orasure.com |
www.orasure.com |
|
www.orasure.com |
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024